Multiply Labs and Legend Biotech have announced a strategic collaboration aimed at transforming cell therapy production through advanced robotics. This partnership between Multiply Labs, renowned for its innovative automation systems, and Legend Biotech, celebrated for its role in developing the CAR-T therapy Carvykti with Johnson & Johnson, promises to accelerate the adoption of robotic technology in the cell therapy industry. The collaboration aspires to modernize and enhance the efficiency of the cell therapy manufacturing process, traditionally dominated by complex and labor-intensive manual methods.
Breaking New Ground in Biotech Automation
Cell therapy production has long relied on skilled professionals to carry out intricate and time-consuming processes manually. Multiply Labs seeks to change this paradigm with state-of-the-art robotics designed to automate these tasks without altering the essential steps of cell production. The robotic system employs modular cubes where robotic arms interact with various instruments, currently managed by human technicians in manual settings. This approach ensures that the cells undergo the same procedures, preserving the integrity and quality of the final product while significantly boosting efficiency.
The Motivation Behind the Alliance
The collaboration highlights a critical need for innovation in the manufacturing landscape of cell therapies. Multiply Labs’ strategy revolves around integrating existing tools and techniques with its robotic systems to minimize disruptions, leading to more streamlined and cost-effective production. By reducing the dependency on costly and scarce skilled labor, this initiative reflects a broader trend toward automation across the biotech sector.
Building on Previous Successes
Multiply Labs’ venture with Legend Biotech follows a series of fruitful collaborations with institutions and companies like Cytiva, UCSF, Thermo Fisher Scientific, and Charles River Laboratories. These partnerships have set the groundwork for the current project, showcasing Multiply Labs’ commitment to pushing the boundaries of cell therapy manufacturing. The company’s proactive stance is further evidenced by recent alliances with Akron Bio, Wilson Wolf, GenScript, and Stanford Medicine. Notably, a large study with Stanford Medicine’s Laboratory for Cell & Gene Medicine is underway to demonstrate the capabilities of Multiply Labs’ robotic systems, likely drawing more stakeholders’ interest.
The Road Ahead for Cell Therapy Manufacturing
Multiply Labs and Legend Biotech have entered into a strategic partnership designed to revolutionize cell therapy production through state-of-the-art robotics. The partnership has high aspirations to make cell therapy manufacturing more efficient, reliable, and scalable. By leveraging Multiply Labs’ expertise in automation and Legend Biotech’s groundbreaking work in cell therapies, the collaboration aims to set new industry standards. This move marks a significant effort to modernize the labor-heavy process, thus potentially making advanced treatments more accessible to patients. Ultimately, this alliance could be a game-changer, increasing both the speed and quality of cell therapy production, thereby transforming the landscape of modern medicine.
